Navigation Links
UC Davis researchers discover molecular target for the bacterial infection brucellosis
Date:8/15/2013

(SACRAMENTO, Calif.) UC Davis scientists have uncovered a potential drug target for the development of an effective therapy against the debilitating, chronic form of the bacterial disease brucellosis, which primarily afflicts people in Mediterranean and Middle Eastern countries.

Brucellosis, which affects about 500,000 people worldwide each year, typically is caused by ingestion of unsterilized milk or close contact with body secretions from infected animals. Symptoms include intermittent or irregular fever of variable duration, headache, weakness, profuse sweating, chills, weight loss and generalized aching. It can also cause long-lasting or chronic symptoms such as recurrent fevers, joint pain and fatigue.

In a paper published online this week in the journal Cell Host & Microbe, the researchers reported that they have identified the cells that harbor the B. abortus bacteria during the persistent phase of the brucellosis. The cells, known as alternatively activated macrophages (AAMs), are a recently identified category of immune defense cells.

The researchers also determined that the biological pathway peroxisome proliferator activated receptor γ, abbreviated as PPARγ, is responsible for altering the metabolism of AAMs so that they supply B. abortus with the energy in the form of glucose that enables bacteria to survive and replicate and thereby sustain the chronic phase of the infectious disease. Other labs also have shown that PPARγ control a cell's metabolism.

"We found that PPARγ induces a metabolic shift in these cells that causes them to generate glucose," said Renee Tsolis, associate professor of medical microbiology and immunology at UC Davis who led the study.

"Starving the B. abortus bacteria by inhibiting the PPARγ pathway may be a new approach to eradicating the chronic, difficult-to-treat form of Brucellosis infection that usually occurs becaus
'/>"/>

Contact: Carole Gan
carole.gan@ucdmc.ucdavis.edu
916-734-9047
University of California - Davis Health System
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UC Davis study deflates notion that pear-shaped bodies more healthy than apples
2. UC Davis researchers aid effort to sequence the complex wheat genome
3. UC Davis researchers develop new drug delivery system for bladder cancer using nanoparticles
4. UC Davis study finds that above-normal weight alone does not increase the short-term risk of death
5. UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer
6. Researchers report a critical role for the complement system in early macular degeneration
7. Researchers study seleniums effects on horses
8. Researchers discover protein that helps plants tolerate drought, flooding, other stresses
9. Fresh analysis of dinosaur skulls by penn researchers finds 3 species are 1
10. HSCI researchers extend human epigenomic map
11. Researchers re-evaluate swine nutrition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... UT Southwestern neuroscience researchers have identified a gene that controls ... mice often used to study addiction and behavior patterns. ... , determines how mammals respond to cocaine, although it is ... or for addiction, said Dr. Joseph Takahashi , chair ...
... Department of Energy,s Brookhaven National Laboratory have identified a ... class of plant products with a wide range of ... source of flavors, fragrances, and pigments; some are of ... contribution to the construction of plant cell walls, (poly)phenols ...
... of superstars in the materials world. Already prized for ... identity, vanadium dioxide can now add muscle power to ... Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... from vanadium dioxide that for its size is a ...
Cached Biology News:UT Southwestern neuroscience researchers identify gene involved in response to cocaine 2Enlisting cells' protein recycling machinery to regulate plant products 2A micro-muscular breakthrough 2A micro-muscular breakthrough 3
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Approval of Genasense in Relapsed/Refractory Patients, BERKELEY ... GNTA ) announced that the Company has completed ... Janet Woodcock, Acting,Director of the Center for Drug ... Administration (FDA). The appeal asks that CDER approve ...
... Cell,Genesys, Inc. (Nasdaq: CEGE ), today announced ... and Sharon E. Tetlow, senior,vice president and chief financial ... to the company,s third quarter financial results,that will be ... at 2:00 p.m. PT/ 5:00 p.m. ET. The ...
... Include World-Renowned RNase and RNA Researchers, SOMERSET, ... of ribonuclease (RNase) therapeutics will be the focus ... by Alfacell,Corporation (Nasdaq: ACEL ). Moderated ... officer, and David Sidransky, M.D., Alfacell,s scientific,advisory board ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4